Tests a pig kidney transplant in adults with end-stage kidney disease
Tests whether a pig kidney can work without dialysis in adults with kidney failure.
Plain-language title generated from the registry record
Registry title: Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease
Key facts
- Where
- New York, United StatesSee the 2 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07696962, who can take part
Where in United States
- New YorkNew York, United StatesNot yet recruiting
- NYU Langone HealthNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xeno Holdings (US), LLC dba ChoironeX
- Trial code
- NCT07696962
- Record updated
- 10 November 2026
- Original description
The goal of this clinical trial is to learn if a GalKO Porcine Thymokidney can maintain renal function, without the need for dialysis, after transplantation into adult subjects with End Stage Renal Disease.Read full original descriptionShow less
Phase 1 Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease
The goal of this clinical trial is to learn if a GalKO Porcine Thymokidney can maintain renal function, without the need for dialysis, after transplantation into adult subjects with End Stage Renal Disease.
Inclusion: ESRD receiving hemodialysis or peritoneal dialysis for ≥6 months; Eligible for kidney transplantation per site criteria; <50% likelihood of receiving a standard deceased-donor kidney transplant within 12 months; Blood type and immunologic compatibility with study transplant confirmed by testing; EBV seropositive; Up to date on recommended vaccinations for immunocompromised individuals; Willing to use protocol-required contraception; Able to provide informed consent and comply with lifelong follow-up.
Exclusion: Requirement for multi-organ transplantation; Polycystic kidney disease without prior native nephrectomy; Current drug or alcohol misuse; Malignancy within 5 years prior to enrollment, excluding adequately treated non-melanoma skin cancer; Current systemic immunosuppressive therapy (excluding permitted corticosteroids); Participation in another interventional drug trial within 60 days prior to enrollment; Kidney disease with high risk of post-transplant recurrence; History of non-adherence to medical treatment; Significant uncontrolled psychiatric illness; Serious non-renal illness with life expectancy <1 year; Known hypercoagulable disorder; Uncontrolled hypertension or hemodynamic instability at enrollment; Clinically significant cardiovascular disease, including poorly controlled coronary artery disease, reduced left ventricular function, recent myocardial infarction or cardiac intervention, or clinically significant arrhythmia requiring treatment; Serious liver disease or impaired liver function; Active infection at time of transplantation; Positive serology for hepatitis B, hepatitis C, or HIV; Current, active, or untreated tuberculosis; Known severe hypersensitivity to a required study medication with no acceptable alternative; Diabetes mellitus with poor glycemic control (HbA1c >10%); Living donor available who is ABO-incompatible; Unable or unwilling to comply with study procedures; Identified as vulnerable by psychological assessment; Inadequate social support or caregiver unavailable/unwilling; BMI <16 or >35 kg/m²; Pregnant or breastfeeding.